DXCM:NSD-DexCom Inc (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 71.66

Change

+0.88 (+1.24)%

Market Cap

USD 23.46B

Volume

2.46M

Analyst Target

USD 475.06
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-25 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
PODD Insulet Corporation

+1.33 (+0.51%)

USD 17.22B
MASI Masimo Corporation

+1.11 (+0.68%)

USD 7.80B
BRKR Bruker Corporation

+0.10 (+0.26%)

USD 5.53B
IRTC iRhythm Technologies Inc

+1.21 (+1.15%)

USD 3.28B
PRCT Procept Biorobotics Corp

-0.07 (-0.13%)

USD 2.85B
TMDX TransMedics Group Inc

-0.68 (-0.72%)

USD 2.73B
QDEL Quidel Corporation

+0.31 (+1.12%)

USD 2.42B
LIVN LivaNova PLC

N/A

USD 1.95B
NVCR Novocure Ltd

-0.05 (-0.27%)

USD 1.81B
UFPT UFP Technologies Inc

-0.09 (-0.04%)

USD 1.62B

ETFs Containing DXCM

CYBG:LSE VanEck Bionic Engineering.. 9.88 % 0.00 %

+0.09 (+0%)

N/A
EDOC:AU 8.18 % 0.00 %

N/A

N/A
CIB0:XETRA VanEck Bionic Engineering.. 8.05 % 0.00 %

+0.07 (+0%)

N/A
EKG First Trust Nasdaq Lux Di.. 7.17 % 0.00 %

-0.04 (0%)

USD 2.29M
SANE 6.79 % 0.00 %

N/A

N/A
CURG:LSE VanEck Genomics and Healt.. 6.63 % 0.00 %

+0.07 (+0%)

USD 4.76M
CURE:XETRA VanEck Genomics and Healt.. 6.37 % 0.00 %

+0.05 (+0%)

N/A
SNSG:LSE Global X Internet of Thin.. 5.60 % 0.00 %

+0.10 (+0%)

USD 2.54M
FDOC:LSE 4.89 % 0.00 %

N/A

N/A
WELL:PA HAN-GINS Indxx Healthcare.. 4.70 % 0.00 %

+0.06 (+0%)

N/A
WELL:SW HAN-GINS Indxx Healthcare.. 4.70 % 0.00 %

+0.16 (+0%)

N/A
DIP 4.61 % 0.00 %

N/A

N/A
FDHT:XETRA 4.55 % 0.00 %

N/A

N/A
SN5R:XETRA Global X Internet of Thin.. 4.47 % 0.00 %

+0.11 (+0%)

USD 3.06M
SNSR:SW Global X Internet of Thin.. 4.47 % 0.00 %

+0.14 (+0%)

USD 2.40M
MEDI Harbor Health Care ETF 4.45 % 0.00 %

+0.20 (+0%)

USD 0.01B
DDOC:F Global X Telemedicine & D.. 4.33 % 0.00 %

+0.17 (+0%)

N/A
FDHT Fidelity Covington Trust .. 4.07 % 0.00 %

+0.26 (+0%)

USD 7.77M
UMDV:SW iShares US Medical Device.. 4.00 % 0.00 %

N/A

N/A
HLTH:AU VanEck Global Healthcare .. 2.73 % 0.00 %

N/A

USD 0.06B
ESGX 2.29 % 0.00 %

N/A

N/A
BFIT 0.00 % 0.50 %

N/A

N/A
IHI iShares U.S. Medical Devi.. 0.00 % 0.43 %

+0.29 (+0%)

N/A
LNGR 0.00 % 0.50 %

N/A

N/A
ZHU:CA BMO Equal Weight US Healt.. 0.00 % 0.00 %

+0.17 (+0%)

CAD 0.01B
GDNA 0.00 % 0.00 %

N/A

N/A
SLIM 0.00 % 0.50 %

N/A

N/A
SNSR Global X Internet of Thin.. 0.00 % 0.69 %

+0.06 (+0%)

USD 0.21B
ZUH:CA BMO Equal Weight US Healt.. 0.00 % 0.39 %

-0.84 (0%)

CAD 0.21B
DBPD:F Xtrackers - ShortDAX x2 D.. 0.00 % 0.00 %

-0.02 (0%)

N/A
W311:XETRA HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

+0.05 (+0%)

N/A
EDOC Global X Telemedicine & D.. 0.00 % 0.00 %

N/A

USD 0.03B
DDOC:XETRA Global X Telemedicine & D.. 0.00 % 0.00 %

-0.02 (0%)

N/A
IMCG iShares Morningstar Mid-C.. 0.00 % 0.00 %

+0.04 (+0%)

N/A
W311:F HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

N/A

N/A
CVGB:LSE 0.00 % 0.00 %

N/A

N/A
CAVE:LSE 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.86% 70% C- 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.86% 70% C- 51% F
Trailing 12 Months  
Capital Gain -42.37% 41% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -42.37% 41% F 24% F
Trailing 5 Years  
Capital Gain -13.78% 74% C 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -13.78% 74% C 34% F
Average Annual (5 Year Horizon)  
Capital Gain -0.12% 50% F 41% F
Dividend Return -0.12% 50% F 37% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 34.89% 72% C 52% F
Risk Adjusted Return -0.33% 50% F 37% F
Market Capitalization 23.46B 100% F 97% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.